T1	Participants 47 159	patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus
T2	Participants 175 204	36 patients treated in France
T3	Participants 286 338	patients with metastatic renal cell carcinoma (mRCC)
T4	Participants 561 627	patients with disease progression after a TKI-everolimus sequence.
T5	Participants 672 777	patients enrolled in RECORD-1 (Renal Cell Cancer Treatment With Oral RAD001 Given Daily) at French sites.
T6	Participants 921 940	Thirty-six patients
